| 10.04.17 | CytomX lines up another big biobucks deal; New I-O player Palleon gains $48M, pharma backing

Click here to subscribe to Fiercebiotech.com

7 years ago

Html
Text

To view this email as a web page, click here

This week's sponsor is Premier Research.
	iRECIST: The Future of Solid Tumor Evaluation? The iRECIST guidance on solid tumor response focuses new attention on standardizing and validating immune response criteria. Will it be the new standard for clinical trials? See what our experts think. Premier Research. It's what we do. Best.

Today's Rundown

Amgen pens CytomX I-O pact with major biobucks promise

Startup Palleon has a sweet plan for cancer immunotherapy

Motif Bio phase 3 hits endpoint, teeing up date with FDA

[Sponsored] End-to-End Drug & Diagnostic Development Support For A New Immuno Oncology Agent

Amgen helps Immatics to $58M round to fund cancer trials

After a recent failure, Catabasis uses open-label data for phase 3 push

Thync’s bioelectronics wearable shows promise in psoriasis pilot

Mylan surprises analysts, Teva with long-delayed Copaxone approvals

Featured Story

Amgen pens CytomX I-O pact with major biobucks promise

Wednesday, October 4, 2017

Just a few months after Fierce 15 winner CytomX signed a major $3.6 billion biobucks deal with Bristol-Myers Squibb, the biotech is at it again, this time with Amgen.

This week's sponsor is Deloitte.

Startup Palleon has a sweet plan for cancer immunotherapy

Wednesday, October 4, 2017

The immuno-oncology sector has a new player. Massachusetts startup Palleon Pharmaceuticals has raised $47.6 million to fund the development of drugs that target sugar-sensing molecules on the surfaces of cells.

Motif Bio phase 3 hits endpoint, teeing up date with FDA

Wednesday, October 4, 2017

A second phase 3 trial of Motif Bio’s antibiotic iclaprim has hit its primary endpoint. The data tee Motif Bio up to file for approval of a drug that was knocked back by the FDA in 2009 and almost sunk the biotech 12 months ago.

[Sponsored] End-to-End Drug & Diagnostic Development Support For A New Immuno Oncology Agent

Thursday, September 28, 2017

Learn how one company sought support at multiple junctures—from manufacturing to biomarker evaluation to market access—to enable a faster and more effective launch of their new programmed death receptor-1 (PD-1)-blocking antibody.

Amgen helps Immatics to $58M round to fund cancer trials

Wednesday, October 4, 2017

Immatics has raised $58 million (€49 million) to push its cancer immunotherapies deeper into the clinic. The German T-cell specialist turned to its existing investors and new partner Amgen to put together the round, which brings its amount raised to date up toward €200 million.

After a recent failure, Catabasis uses open-label data for phase 3 push

Wednesday, October 4, 2017

Catabasis Pharmaceuticals is looking to test its experimental Duchenne drug edasalonexent in a late-stage trial after posting the last of the data from its midstage work.

Thync’s bioelectronics wearable shows promise in psoriasis pilot

Wednesday, October 4, 2017

Thync, which markets wearables that help users sleep better or relax, reported the first effective use of bioelectronics to treat psoriasis in a pilot study. The noninvasive therapy “significantly” reduced psoriasis symptoms and could fill a gap in psoriasis treatment.

Mylan surprises analysts, Teva with long-delayed Copaxone approvals

Wednesday, October 4, 2017

Mylan’s long been frustrated by a pair of delays for high-profile generic products. But on Tuesday evening, it picked up an approval for one of them—and it came at Teva’s expense.

This week's sponsor is QuintilesIMS.
	Confidence for Emerging Biopharma Your evidence generation plan is key to stakeholder approvals and optimal asset valuation. Develop and deliver it with confidence. Explore More.